Saturday 17 October 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 40.0% and free cash flow grew 64.7%, each against the same quarter a year earlier.
142.78
9.84
−6.45%
Follow BLTE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
34.37 | 49.08 | 33.71 | 33.56 |
Net Debt/EBITDA |
11.97 | 17.61 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.23 | 0.41 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (1.52) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Free Cash Flow per Share |
(0.80) | (0.31) | 0.00 | 0.00 | |
Cash per Share |
8.30 | 14.68 | 0.00 | 0.00 | |
Shareholders Equity per Share |
8.25 | 22.97 | 19.96 | 19.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.25 | 22.97 | 19.96 | 19.33 | |
Free Cash Flow |
(26.60) | (10.56) | — | — | |
Working Capital |
269.15 | 484.20 | 506.38 | 486.65 | |
Capital Expenditures |
— | (0.18) | — | — | |
Net Current Asset Value |
268.90 | 484.20 | 506.38 | 486.65 | |
| Other line items | |||||
Quick Ratio |
34.17 | 48.97 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.80) | (0.31) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Average Assets |
199.11 | 466.34 | 487.74 | 473.99 | |
Average Common Equity |
164.90 | 411.64 | — | — | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates